This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
CP-547632 TFA
Catalog No. T74000 CAS
2805804-54-8
CP-547632 TFA is an orally active, ATP-competitive inhibitor that potently targets VEGFR-2 and FGF kinases with IC50 values of 11 nM and 9 nM, respectively. It demonstrates selectivity for VEGFR-2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs), exhibiting antitumor efficacy [1].
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
Contact us for more batch information
Biological Description
Chemical Properties
Storage
& Solubility Information
Description
CP-547632 TFA is an orally active, ATP-competitive inhibitor that potently targets VEGFR-2 and FGF kinases with IC50 values of 11 nM and 9 nM, respectively. It demonstrates selectivity for VEGFR-2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs), exhibiting antitumor efficacy [1].
Targets&IC50
FGFR:9 nM, VEGFR2:11 nM
In vitro
CP-547632 TFA (1-1000 nM; 1 hour) dose-dependently inhibits VEGF-induced VEGFR-2 phosphorylation, achieving an IC50 of 6 nM [1].
In vivo
CP-547632 TFA, when administered orally in doses ranging from 6.25 to 100 mg/kg/day over a period of 10-24 days, results in a dose-dependent suppression of tumor growth in Colo-205, DLD-1, and MDA-MB-231 xenografts [1]. A single oral dose of 50 mg/kg produces plasma concentrations exceeding 500 ng/ml for a duration of up to 12 hours [1].
Molecular Weight
646.43
Formula
C22H25BrF5N5O5S
CAS No.
2805804-54-8
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.